Axsome Therapeutics
$178
133
-$5.72-3.11% Today
Statistics
Day High
186
Day Low
181.5
52W High
189.1
52W Low
95.65
Volume
566,044
Avg. Volume
628,658
Mkt Cap
8.97B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
23FebExpected
Expected EPS
-0.72
Actual EPS
-0.56
Financials
-74.47%Profit Margin
Unprofitable771.39MRevenue
-574.43MNet Income
Analyst Ratings
$217.33Average Price Target
The highest estimate is 260.00.
From 12 ratings within the last 6 months. This is not an investment recommendation.
From 12 ratings within the last 6 months. This is not an investment recommendation.
Buy 92%
Hold 8%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow AXSM. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Alkermes
ALKS
Mkt Cap5.07B
Johnson & Johnson
JNJ
Mkt Cap455.04B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Novartis
NVS
Mkt Cap237.61B
Bristol-Myers Squibb
BMY
Mkt Cap93.79B
Pfizer
PFE
Mkt Cap140.15B
Merck
MRK
Mkt Cap214.76B
Abbvie
ABBV
Mkt Cap385.18B
About
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
Show more...
CEO
Dr. Herriot Tabuteau M.D.
Employees
712
Country
US
ISIN
US05464T1043
Listings
0 Comments
Share your thoughts
FAQ
What is Axsome Therapeutics stock price today?▼
The current price of AXSM is $178 USD — it has decreased by -3.11% in the past 24 hours. Watch Axsome Therapeutics stock price performance more closely on the chart.
What is Axsome Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Axsome Therapeutics stocks are traded under the ticker AXSM.
Is Axsome Therapeutics stock price growing?▼
AXSM stock has fallen by -0.67% compared to the previous week, the month change is a -3.2% fall, over the last year Axsome Therapeutics has showed a +30.67% increase.
What is Axsome Therapeutics market cap?▼
Today Axsome Therapeutics has the market capitalization of 8.97B
What were Axsome Therapeutics earnings last quarter?▼
AXSM earnings for the last quarter are -0.56 USD per share, whereas the estimation was -0.72 USD resulting in a +22.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Axsome Therapeutics revenue for the last year?▼
Axsome Therapeutics revenue for the last year amounts to 771.39M USD.
What is Axsome Therapeutics net income for the last year?▼
AXSM net income for the last year is -574.43M USD.
How many employees does Axsome Therapeutics have?▼
As of February 23, 2026, the company has 712 employees.
In which sector is Axsome Therapeutics located?▼
Axsome Therapeutics operates in the Health Care sector.
When did Axsome Therapeutics complete a stock split?▼
Axsome Therapeutics has not had any recent stock splits.
Where is Axsome Therapeutics headquartered?▼
Axsome Therapeutics is headquartered in New York, US.